Effectiveness of Behavioral Activation Treatment for Schizophrenia

Sponsor
Inha University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05764148
Collaborator
(none)
80
1
2
34
2.4

Study Details

Study Description

Brief Summary

The purpose of this study is to implement a behavior activation remote program for negative symptoms of schizophrenia and to verify whether the behavior activation remote program for negative symptoms of schizophrenia has effects on negative symptoms, cognitive function, and social function of schizophrenia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: behavioral activation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
schizophrenia group and treatment as usualschizophrenia group and treatment as usual
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Non Face-to-face Behavioral Activation Treatment for Negative Symptoms of Schizophrenia
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Behavioral activation

Behavioral activation

Behavioral: behavioral activation
Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring. Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions.

Placebo Comparator: Traatment as usual

Behavioral: behavioral activation
Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring. Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions.

Outcome Measures

Primary Outcome Measures

  1. negative function [three month]

    improved negative function

Secondary Outcome Measures

  1. cognitive function [three month]

    improved cognitive function

  2. depressed mood [three month]

    improved depressed mood

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients who have received a primary diagnosis of schizophrenia

  • Patients who are at least 18 years old and under 65 years old

  • Patients who show a score of 3 or higher on at least two negative symptom items in the Positive and Negative Syndrome Scale (PANSS)

  • The subject selection period is until December 31, 2021, from the IRB approval date.

Exclusion Criteria:
  • Patients with a history of organic brain syndrome, epilepsy, or traumatic brain injury

  • Patients with comorbidities such as intellectual disability, current alcohol or other substance dependence

  • Patients who show a score of 5 or higher on at least two positive symptom items in the Positive and Negative Syndrome Scale (PANSS)

  • Patients who have received a diagnosis of major depressive disorder according to the DSM-V criteria by a specialist in psychiatry

  • Patients who have received psychological services including components of behavioral activation therapy

  • Patients who are at risk of self-harm or harm to others.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Inha university hospital Incheon Jung-Gu Korea, Republic of 22332

Sponsors and Collaborators

  • Inha University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wonhyoung Kim, Associated professor, Inha University Hospital
ClinicalTrials.gov Identifier:
NCT05764148
Other Study ID Numbers:
  • 2021-01-026
First Posted:
Mar 10, 2023
Last Update Posted:
Mar 10, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wonhyoung Kim, Associated professor, Inha University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2023